AMS Capital’s Haemonetics HAE Stock Holding History

AMS Capital’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-5,889	Closed	-$675K	–	28
2018 Q3	$675K	Buy	+5,889	New	+$610K	0.56%	36

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AMS Capital's HAE Position: Q4 2018 in Review

AMS Capital sold out of Haemonetics (HAE) in Q4 2018, closing a stake of 5,889 shares — an estimated $675K sold.

AMS Capital first reported a position in HAE in Q3 2018 and held it in 1 quarter. The position peaked at $675K in Q3 2018. 279 funds tracked by Wall St. Rank hold HAE as of Q4 2018.

AMS Capital reported no remaining Haemonetics position as of Q4 2018 after selling out during the quarter.
AMS Capital sold 5,889 Haemonetics shares in Q4 2018, an estimated $675K.
AMS Capital first reported a position in Haemonetics in Q3 2018 and held it in 1 quarter.
AMS Capital's Haemonetics position peaked at $675K in Q3 2018.
279 funds tracked by Wall St. Rank held Haemonetics as of Q4 2018.

Based on AMS Capital's 13F filing for Q4 2018, filed 29 Jan 2019.